Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma.
Wang-Gillam A, Plambeck-Suess S, Goedegebuure P, Simon PO, Mitchem JB, Hornick JR, Sorscher S, Picus J, Suresh R, Lockhart AC, Tan B, Hawkins WG. Wang-Gillam A, et al. Among authors: sorscher s. Invest New Drugs. 2013 Jun;31(3):707-13. doi: 10.1007/s10637-012-9866-y. Epub 2012 Aug 4. Invest New Drugs. 2013. PMID: 22864469 Free PMC article. Clinical Trial.
Why the length of recurrence-free survival or 'lead-times' can be misleading. Comment on: Callesen LB, Takacova T, Hamfjord J, et al. Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis.
Sorscher S. Sorscher S. Ther Adv Med Oncol. 2023 Mar 17;15:17588359231156383. doi: 10.1177/17588359231156383. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 36960320 Free PMC article. No abstract available.
Coexisting KRAS and NRAS mutations in colon cancer.
Sorscher S. Sorscher S. J Clin Pathol. 2015 Dec;68(12):1044. doi: 10.1136/jclinpath-2015-203259. Epub 2015 Aug 4. J Clin Pathol. 2015. PMID: 26243064 No abstract available.
EGFR mutations and sensitivity to gefitinib.
Sorscher SM. Sorscher SM. N Engl J Med. 2004 Sep 16;351(12):1260-1; author reply 1260-1. doi: 10.1056/NEJM200409163511221. N Engl J Med. 2004. PMID: 15371587 No abstract available.
Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma.
Peddi PF, Lubner S, McWilliams R, Tan BR, Picus J, Sorscher SM, Suresh R, Lockhart AC, Wang J, Menias C, Gao F, Linehan D, Wang-Gillam A. Peddi PF, et al. Among authors: sorscher sm. JOP. 2012 Sep 10;13(5):497-501. doi: 10.6092/1590-8577/913. JOP. 2012. PMID: 22964956 Free article. Clinical Trial.
Five fractions of radiation therapy followed by 4 cycles of FOLFOX chemotherapy as preoperative treatment for rectal cancer.
Myerson RJ, Tan B, Hunt S, Olsen J, Birnbaum E, Fleshman J, Gao F, Hall L, Kodner I, Lockhart AC, Mutch M, Naughton M, Picus J, Rigden C, Safar B, Sorscher S, Suresh R, Wang-Gillam A, Parikh P. Myerson RJ, et al. Among authors: sorscher s. Int J Radiat Oncol Biol Phys. 2014 Mar 15;88(4):829-36. doi: 10.1016/j.ijrobp.2013.12.028. Int J Radiat Oncol Biol Phys. 2014. PMID: 24606849 Free PMC article. Clinical Trial.
148 results